The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.

doi:10.3324/haematol.2012.080234

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.

Haematologica - 1 Oct 2013

Nicolini Franck E, Ibrahim Amr R, Soverini Simona, Martinelli Giovanni, Müller Martin C, Hochhaus Andreas, Dufva Inge H, Kim Dong-Wook, Cortes Jorge, Mauro Michael J, Chuah Charles, Labussière Hélène, Morisset Stéphane, Roche-Lestienne Catherine, Lippert Eric, Hayette Sandrine, Peter Senaka, Zhou Wei, Maguer-Satta Véronique, Michallet Mauricette, Goldman John, Apperley Jane F, Mahon François-Xavier, Marin David, Etienne Gabriel

Abstract excerpt

The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed. Using matched pair analysis, a cohort of 64 patients with chronic phase chronic myelogenous leukemia harboring a T315I mutation and resistant to imatinib mesylate was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Drug Resistance, Neoplasm

Share to Fusion Proteins, bcr-abl

Share to Genes, abl

Share to Protein Kinase Inhibitors

Share to Survival Rate

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 23716543
DOI: 10.3324/haematol.2012.080234
PMCID: PMC3789454

Genes

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.PMID 23716543Read ↗

A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective studySemantic proximity Read ↗

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.Semantic proximity Read ↗

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.Semantic proximity Read ↗

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.Semantic proximity Read ↗

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.Semantic proximity Read ↗

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasSemantic proximity Read ↗

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.Semantic proximity Read ↗

Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.Semantic proximity Read ↗

BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.Semantic proximity Read ↗

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.Semantic proximity Read ↗

Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation.Semantic proximity Read ↗

Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.